Compounded vs. FDA-Approved GLP-1 Medications: What Changed and Where That Leaves You

A few years ago, compounded semaglutide and tirzepatide became much more common. At the time, brand-name GLP-1 medications were in short supply, and compounding pharmacies could help fill that gap.

Now, that situation has changed.

The shortages have largely ended, FDA rules have tightened, and many patients are left wondering the same thing: Is compounded semaglutide still legal in 2026? The answer is yes, in some situations, but not as broadly as it was during the shortage.

At Medical Group Texas, we know this can be confusing. The rules have changed quickly, and headlines don’t always make it clear what’s changed. Here is a quick overview: 

Is Compounded Semaglutide Still Legal in 2026?

Yes, but the rules are much narrower now. During the shortage, compounding pharmacies had more flexibility to prepare versions of medications like semaglutide and tirzepatide because FDA-approved products were not consistently available. Once the shortages ended, that broad exception started to fade. The FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025. That means compounded GLP-1 medications are no longer meant to serve as a routine replacement for commercially available brand-name drugs.

Some situations still allow a state-licensed 503A compounding pharmacy to prepare a medication for an individual patient. For example, a patient may have a specific clinical need for a different dose, dosage form, or formulation that is not commercially available.

The key phrase is individual clinical need. Compounding is not meant to be the cheaper version of the brand-name medication.

What Changed With the FDA’s 503B Proposal?

Another type of compounding facility is called a 503B outsourcing facility. You do not need to remember the terminology. 503B facilities operate on a larger scale than traditional patient-specific compounding pharmacies.

In April 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, which governs what those facilities may compound from bulk ingredients. The reasoning was straightforward: FDA-approved versions are now available, so there may no longer be a need to make these drugs from bulk outside a shortage. The comment period closed June 29, 2026. As of September 2026, the proposal has not become a final rule, though it could at any point.

So, is compounded tirzepatide legal in 2026? In certain patient-specific situations, a 503A compounding pharmacy may still make it legal. The large-scale compounding pathway, however, has become much narrower and may tighten further if the FDA finalizes its proposed rule.

Compounded vs Brand-Name GLP-1: What’s the Difference?

Brand-name GLP-1 medications include:

  • Ozempic and Wegovy, which contain semaglutide
  • Mounjaro and Zepbound, which contain tirzepatide

These medications have gone through the FDA approval process, including review of how they are manufactured, their strength, purity, and quality.

Compounded GLP-1 medications are different. A compounded medication is specially prepared by a licensed pharmacy, often to meet a specific patient’s needs. Compounded medications are not individually FDA-approved in the same way as brand-name products. 

That does not automatically mean a compounded medication is inappropriate. It does mean patients should understand exactly what they are receiving, why it is being recommended, and where it is coming from. 

Some compounded GLP-1 medications may also include additional ingredients, such as B vitamins. That is another reason to ask your physician exactly what is in your medication rather than assuming every semaglutide or tirzepatide product is the same.

How Do You Determine Which Option Is Right for You?

The right GLP-1 option depends on more than what is available or what costs less. Your health history, current medications, metabolic health, and treatment goals all matter, along with how you have responded to weight loss medications before.

At Medical Group Texas, we look at the full picture before recommending a weight loss protocol. That includes helping you understand:

  • Whether your medication is FDA-approved or compounded
  • Why one option may make more sense for you
  • Where your medication is coming from
  • What ingredients are in the formulation
  • How your treatment will be monitored over time

A good treatment plan should come with clear answers, not guesswork.

What If You’re Already Using a Compounded GLP-1?

If you are already using compounded semaglutide or tirzepatide, do not panic. But now is a good time to talk with your prescribing physician. Ask whether your current medication still makes sense under today’s rules. You may also want to discuss whether moving to an FDA-approved product fits your health goals, treatment plan, and budget.

Do not stop, switch, or change your medication on your own. Your physician can help you understand your options and make a safe transition if needed.

Why Medical Oversight Matters More Than Ever

GLP-1 medications can be powerful tools, but they are not one-size-fits-all. The medication itself is only one part of the treatment plan. Your physician should also review your lab work, metabolic health, medications, side effects, progress, and overall response.

At Medical Group Texas, weight loss care goes beyond writing a prescription. We continue to monitor your progress so your plan can change as your needs change. Ongoing medical oversight matters, especially as the regulatory setting around compounded GLP-1 medications changes.

Physician-Supervised Weight Loss, Built Around You

The rules surrounding compounded vs brand-name GLP-1 medications have changed significantly, but you do not have to sort through those changes alone. Medical Group Texas helps patients understand the options that are currently available and choose a treatment plan. 

If you are considering semaglutide, tirzepatide, or another GLP-1 medication, or if you are already using a compounded version and wondering what the recent FDA changes mean for you, schedule a consultation with Medical Group Texas.

We can help you understand your options and build a physician-supervised weight loss plan that fits where you are now.

Sources
U.S. Food and Drug Administration. “FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List.”
https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list 
Federal Register. “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act.”
https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal 
Disclaimer: Medical weight loss treatments, including GLP-1 medications and compounded medications when appropriate, are not suitable for every patient. Eligibility, medication selection, dosing, and results vary based on individual health history, lab work, medications, and clinical needs. Weight loss results are not guaranteed, and all treatment should be provided under the supervision of a qualified medical professional.
Disclaimer: The information provided in this article is for general educational purposes only and is not intended to replace individualized medical advice, diagnosis, or treatment. Medical needs and outcomes vary from person to person. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, supplement, or treatment plan.